AbbVie to Acquire Pharmacyclics: What it Means For Mutual Fund Investors (ABBV, PCYC)
Shauna O'Brien Mar 05, 2015
Inside the Deal
This is the first deal that the company has made since its terminated deal to acquire Ireland-based Shire.
Shares of ABBV dropped 2.5% on the news, while PCYC sales surged over 10%.
AbbVie’s Drug Pipeline
Despite the opportunity, shares of ABBV are down today, as many analysts see PCYC’s Imbruvica drug as unable to meet ambitious sales estimates.
Mutual Funds to Watch
|VTSMX||Vanguard Total Stock Mkt Idx||1.64%|
|VFINX||Vanguard 500 Index||1.10%|
The Bottom Line
If you’ve enjoyed this article, sign up for the free MutualFunds.com newsletter; we’ll send you similar content weekly.
Sign up for Advisor Access
Receive email updates about best performers, news, CE accredited webcasts and more.